A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

NCT00236574 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

974

Enrollment

INDUSTRY

Sponsor class

Conditions

Dementia
Alzheimer Disease

Interventions

DRUG: Galantamine hydrobromide

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.